Agenda
Objectives:
- To share the latest progress on NCI-funded research related to the basic biological mechanisms and therapeutic targeting of fusion oncoproteins in childhood cancer.
- To exploit the synergy of this multi-disciplinary group to address shared challenges and advance common goals.
Wednesday, September 9, 2020
Chemistry for Targeting Fusions and Downstream Pathways
Moderator: Eric Fischer, Dana-Farber Cancer Institute
Keren Witkin - National Cancer Institute
Nathanael Gray - Dana-Farber Cancer Institute
John H. Bushweller - University of Virginia School of Medicine
David McFadden - UT Southwestern
Break
Sanford Simon - The Rockefeller University
Aykut Uren - Georgetown University
Siwen Kang - Nationwide Children's Hospital
Group Discussion
Confidentiality Clause
The Annual Meeting for the Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium may include confidential information as part of materials provided, presentations, and discussions. Confidential information presented at this meeting should not be disclosed outside of this Consortium and its invited guests, and care should be taken to maintain the confidentiality of all such information. Confidential information may include, but is not limited to, unpublished data, research results, theories, drawings and figures or visual depictions of research data or results regardless of format.
Thursday, September 10, 2020
Phase Separation
Moderator: Richard Kriwacki, St. Jude Children's Research Hospital
Invited Speaker, Clifford Brangwynne - Princeton University
Jacob C. Schwartz - University of Arizona
Break
Invited Speaker, Richard Young - Whitehead Institute/MIT
Bappaditya Chandra - St. Jude Children's Research Hospital
Shasha Chong - University of California Berkeley
Group Discussion
Confidentiality Clause
The Annual Meeting for the Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium may include confidential information as part of materials provided, presentations, and discussions. Confidential information presented at this meeting should not be disclosed outside of this Consortium and its invited guests, and care should be taken to maintain the confidentiality of all such information. Confidential information may include, but is not limited to, unpublished data, research results, theories, drawings and figures or visual depictions of research data or results regardless of format.
Friday, September 11, 2020
Chromatin Remodeling
Moderator: Cigall Kadoch, Dana-Farber Cancer Institute
Beat W. Schäfer - University Children's Hospital Zürich
Marc Morgan - Northwestern University
Kevin Jones - Huntsman Cancer Institute/University of Utah
Group Discussion 1
Break
Richard J. Gilbertson - University of Cambridge
Iftekhar A. Showpnil - Nationwide Children’s Hospital
Miguel N. Rivera - Massachusetts General Hospital/ Dana-Farber Cancer Institute
Group Discussion 2
Discussion Leader: Kimberly Stegmaier - Dana-Farber Cancer Institute, FusOnC2 Steering Committee Chair
Confidentiality Clause
The Annual Meeting for the Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium may include confidential information as part of materials provided, presentations, and discussions. Confidential information presented at this meeting should not be disclosed outside of this Consortium and its invited guests, and care should be taken to maintain the confidentiality of all such information. Confidential information may include, but is not limited to, unpublished data, research results, theories, drawings and figures or visual depictions of research data or results regardless of format.